Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes, Type I Clear all
Recruiting Not applicable Interventional

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

NCT07386340
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

NCT02384941
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Early Phase 1 Interventional

A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes

NCT04712266
View directory record Official record
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Abvance Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes

NCT00315939
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1), Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
Device
Lead sponsor
Boris Kovatchev, PhD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Sep 30, 2026, 9:02 PM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 30, 2026, 9:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT06783309
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions
CNP-103, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Sep 30, 2026, 9:02 PM EDT
Suspended Phase 1 Interventional

Islet Allotransplantation in Type 1 Diabetes

NCT01705899
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Human Pancreatic Islets
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2033
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

NCT04585776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
LY900014, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial

NCT03195140
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Predictive Low Glucose Suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Santa Barbara, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Sep 30, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

NCT06411210
View directory record Official record
Conditions
Diabetes type1, Obesity
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 30, 2026, 9:02 PM EDT
Recruiting No phase listed Observational

EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

NCT03369821
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Beta Cell Loss and Immune Function, Immune Function with RNAseq
Diagnostic Test · Other
Lead sponsor
University of Exeter
Other
Eligibility
Up to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 9:02 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

NCT01515384
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
18F-AV-133
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 30, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

NCT00143247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exubera® (inhaled insulin)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
12
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)

NCT01563887
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
DD.com, DD.com + MI
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
568 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 30, 2026, 9:02 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Combined Antibody Screening for Celiac and Diabetes Evaluation

NCT04677699
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Combined Risk Score
Diagnostic Test
Lead sponsor
Pacific Northwest Research Institute
Other
Eligibility
1 Day to 7 Years
Enrollment
64,410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Early Phase 1 Interventional

Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D

NCT05847413
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Verapamil
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BGAT (Blood Glucose Awareness Training) for Users Who Might Become Pregnant

NCT02508779
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Pregnancy
Interventions
Bump2be, Routine Care
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 30, 2026, 9:02 PM EDT
Completed No phase listed Observational

Sleep, Glycemic Control, and Insulin Resistance in Adolescents With Type 1 Diabetes

NCT03832790
View directory record Official record
Conditions
Type1diabetes, Adolescent Behavior, Sleep
Interventions
observation
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 19 Years
Enrollment
23 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 30, 2026, 9:02 PM EDT
Not listed No phase listed Observational

Accuracy of Blood Glucose Detection by Diabetes Alert Dogs

NCT02126605
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional

A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use

NCT01669473
View directory record Official record
Conditions
Diabetes Mellitus Type I, Diabetes Mellitus Type II
Interventions
EHR Based Strategy to promote Safe and Appropriate Drug Use
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

NCT02656069
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
6
States / cities
Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

NCT01986231
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

NCT03651622
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Overweight and Obesity
Interventions
Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Sep 30, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

NCT03895437
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Sep 30, 2026, 9:02 PM EDT